A Phase 1/2, First-in-Human, Double-Masked, Placebo- Controlled, Dose-Escalation Study Evaluating the Safety, Tolerability, and Efficacy of RU-101 Ophthalmic Solution in Patients with Severe Dry Eye

ID Number 13-1663

Principal Investigator(s)
Penny A Asbell

Department(s) or Division(s)


The study is trying to see whether an experimental drug RU-101 will be a good treatment for severe dry eye disease.RU-101 is a drop that contains protein called recombination human serum albumin(rHSA). Researchers want to find out if albumin can prevent some of the problems caused by dry eye if the albumin drops can hold water and then release it onto the eye surface. The main goal of this study is to evaluate safety and tolerability of repeated use of RU-101. The effects on signs and symptoms of dry eye will also be studied.

Contact Information
Safwan Kezbor
(212) 824-7644

Recruiting Patients: Yes